Preserve the US interchangeable standard that has helped drive physician and patient confidence in biosimilars

Abstract: The US FDA proposed eliminating the distinction between biosimilars and interchangeable biosimilars, aiming to align with European policy and enhance biosimilar uptake. However, this move is misguided, as biosimilars… Read More »